𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

✍ Scribed by Hochhaus, A; La Rosée, P

Book ID
110055950
Publisher
Nature Publishing Group
Year
2004
Tongue
English
Weight
187 KB
Volume
18
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Significance of myelofibrosis in early c
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
✍ Hagop M. Kantarjian; Carlos E. Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND Myelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. ## METHODS The current study evaluated the significance of the

Granulocyte–colony-stimulating factor (f
Granulocyte–colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia
✍ Alfonso Quintas-Cardama; Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Maner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract ## BACKGROUND Imatinib mesylate administration has become standard treatment for patients with chronic myelogenous leukemia (CML). Although the safety profile of imatinib is favorable, Grade ≥ 3 neutropenia (according to the National Cancer Institute Common Toxicity Criteria) occurs in

Imatinib mesylate therapy reduces bone m
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
✍ Carlos E. Bueso-Ramos; Jorge Cortes; Moshe Talpaz; Susan O'Brien; Francis Giles; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 1 views

## Abstract ## BACKGROUND Reticulin‐stained bone marrow fibrosis is associated with a poor prognosis in patients with chronic myelogenous leukemia (CML). Resolution of fibrosis with therapy may improve patient outcome. ## METHODS The effect of imatinib therapy on bone marrow fibrosis was evaluat